ERBB2 and gastric adenocarcinoma: For HER2 overexpression or amplification, known as HER2-positive, HER2-targeted therapies have been demonstrated to improve survival in patients with breast cancer in the adjuvant, neoadjuvant, and salvage settings, as well as in patients with advanced stomach adenocarcinoma (STAD) (1).